Lilly-Boehringer's diabetes treatment does well in late-stage study

08/18/2013 | Genetic Engineering & Biotechnology News

Elderly patients with type 2 diabetes who received Boehringer Ingelheim and Eli Lilly and Co.'s dipeptidyl peptidase-4 inhibitor linagliptin for 24 weeks showed significant reductions in blood glucose levels compared with those treated with a placebo, a late-stage trial found. The safety and tolerability profile was comparable to that of the placebo.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ